arrow
R

Rahul Mannan

university of michigan
H指数:25
被引数:3,405

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Discovery and preclinical evaluation of ZLC853 as a potential clinical candidate covalently targeting CDK12/13 kinases

ZLC853的发现及其作为潜在临床候选药物对CDK12/13激酶的共价靶向作用的临床前评估

2026-07-290
OA
Distinct clinicopathological and survival profiles of CLDN18.2 and PD-L1 expression in advanced gastric cancer and gastroesophageal junction adenocarcinoma

进展期胃癌和胃食管结合部腺癌中CLDN18.2和PD-L1表达的不同临床病理和生存特征

2025-11-010
OAAI
Targeting histone H2B acetylated enhanceosomes via p300/CBP degradation in prostate cancer

通过p300/CBP降解靶向前列腺癌中乙酰化的H2B组蛋白增强子复合物

2025-10-030
OAAI
CDK12/13 inactivation triggers STING-mediated antitumor immunity in preclinical models

CDK12/13失活触发STING介导的抗肿瘤免疫在临床前模型中

2025-09-160
OA
TRIM63 Overexpression in FISH-Negative MiTF Family Altered Renal Cell Carcinoma (MiTF RCC)

TRIM63在FISH阴性MiTF家族改变的肾细胞癌(MiTF RCC)中的过表达

2025-08-250
PREAI
Integrative analysis of lung adenocarcinoma across diverse ethnicities and exposures

不同种族和暴露因素下肺腺癌的整合分析

2025-07-310
OAAI
LSD1+8a is an RNA biomarker of neuroendocrine prostate cancer

LSD1+8a是神经内分泌前列腺癌的RNA生物标志物

2025-05-010
PRE
Targeting PIKfyve-driven lipid metabolism in pancreatic cancer

靶向PIKfyve驱动的脂质代谢在胰腺癌中的应用

NATURE
IF48.5
2025-04-230
OA
Discovery of YJZ5118: A Potent and Highly Selective Irreversible CDK12/13 Inhibitor with Synergistic Effects in Combination with Akt Inhibition

YJZ5118的发现:一种具有协同效应的强效且高度选择性的不可逆CDK12/13抑制剂,可与Akt抑制联合用药。

2025-03-130
PRE
Divergent FOXA1 mutations drive prostate tumorigenesis and therapy-resistant cellular plasticity

不同的FOXA1突变驱动前列腺肿瘤发生和治疗抵抗性细胞可塑性

Science
IF45.8
2025-01-010
OA
Development of an orally bioavailable CDK12/13 degrader and induction of synthetic lethality with AKT pathway inhibition

开发口服生物可利用的CDK12/13降解剂并通过AKT途径抑制诱导合成致死率

2024-10-011
OAAI
CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13
2024-10-010
OAAI
NSD2 is a requisite subunit of the AR/FOXA1 neo-enhanceosome in promoting prostate tumorigenesis
2024-09-092
OAAI
CDK12 loss promotes prostate cancer development while exposing vulnerabilities to paralog-based synthetic lethality
2024-06-100
PRE